MRI-guided BT | Standard BT | |
Intervention period plus 6 weeks | ||
SAE – hospitalisation | 2/5 (40%) | 1/7 (14%) |
Cough | 4/5 (80%) | 6/7 (86%) |
Wheeze | 3/5 (60%) | 4/7 (57%) |
Chest tightness | 1/5 (20%) | 4/7 (57%) |
Consolidation/atelectasis/airspace opacity | 2/5 (40%) | 4/7 (57%) |
Dyspnoea | 2/5 (40%) | 3/7 (43%) |
Chest discomfort | 1/5 (20%) | 3/7 (43%) |
Bronchospasm | 1/5 (20%) | 3/7 (43%) |
Haemoptysis | 0/5 (0%) | 3/7 (43%) |
Productive cough | 1/5 (20%) | 3/7 (43%) |
Decreased breath sounds | 2/5 (40%) | 2/7 (29%) |
Sputum discoloured | 2/5 (40%) | 0/7 (0%) |
Infection | 2/5 (40%) | 1/7 (14%) |
Fever | 1/5 (20%) | 1/7 (14%) |
Night awakenings | 0/5 (0%) | 1/7 (14%) |
Bronchospasm | 0/5 (0%) | 1/7 (14%) |
Post-intervention period (6 weeks–12 months) | ||
SAE – hospitalisation | 1/5 (20%) | 2/7 (29%) |
Cough | 2/5 (40%) | 4/7 (57%) |
Dyspnoea | 3/5 (60%) | 4/7 (57%) |
Chest tightness | 1/5 (20%) | 4/7 (57%) |
Wheeze | 2/5 (40%) | 3/7 (43%) |
Productive cough | 1/5 (20%) | 3/7 (43%) |
Infection | 1/5 (20%) | 3/7 (43%) |
Chest discomfort | 0/5 (0%) | 2/7 (29%) |
Night awakenings | 0/5 (0%) | 2/7 (29%) |
Sputum discoloured | 1/5 (20%) | 1/7 (14%) |
Decreased breath sounds | 1/5 (20%) | 1/7 (14%) |
Fever | 0/5 (0%) | 1/7 (14%) |
Data are presented as n/N (%). MRI: magnetic resonance imaging; BT: bronchial thermoplasty; SAE: severe adverse event.